March 2025

D.Pharma with minimum 55% in aggregate and registered with State Pharmacy Council, Pharmacy Council of India. Individuals qualified in B.Pharma with minimum 50% marks and registered with State Pharmacy Council, Pharmacy Council of India will also be eligible.

Synthesis of polymer conjugates via different chemistry, preparation of microbeads with X-ray imaging moieties, physicochemical characterization, study the drug loading and release kinetics, biocompatibility evaluation, data collection and interpretation, preparation of reports.

Review of environment monitoring records. Sterility testing of the finished products and sterile API. Should have good knowledge in QMS activities.

Analysts to join our Bioanalytical Lab. The role involves conducting bioanalytical testing using LC-MS, MS, method development, method validation and sample analysis. Strong analytical skills, problem-solving abilities, and knowledge of bioanalytical tools are essential. Perform bioanalytical testing for large molecules, including monoclonal antibodies, proteins, and peptides, using immunoassays such as ELISA, MSD, and ligand-binding assays.

AstraZeneca and Alteogen Inc. have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme platform technology. Under the terms of the agreement, AstraZeneca will acquire worldwide rights to use ALT-B4 to develop and commercialise subcutaneous formulations of several oncology assets. Alteogen will be responsible for clinical and commercial supply of ALT-B4 to AstraZeneca.

Zydus Life sciences Limited has received final approval from the United States Food and Drug Administration USFDA to manufacture Apalutamide Tablets, 60 mg.

A previously unknown protein in a family of bacteria found in soil and the human gut microbiome has been discovered – which could help drug delivery in cancer treatment. In a paper published in PNAS, researchers at King’s College London and the University of Washington describe the unique 3D structure of this protein, which is now being used to develop cancer drug delivery systems that can target drugs to tumour sites.

Janus kinase inhibitors are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohns disease or ulcerative colitis. Since their approval, the indications for these medical drugs have steadily increased, but recently safety concerns have also been raised.